DUBLIN, Ireland, March 01, 2016 (GLOBE NEWSWIRE) -- SIGMOID PHARMA LIMITED, a privately-owned, specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases using its proprietary SmPill® solid oral delivery system, announced today that Dr. Ivan Coulter, Chief Executive Officer, will provide a corporate update at the 36th Annual Cowen & Co. Healthcare Conference, taking place in Boston, Massachusetts March 7-9, 2016.
|Title:||36th Annual Cowen & Company Healthcare Conference|
|Time:||10:30am Eastern Time|
|Location:||MIT Room, The Marriott Copley Hotel, Boston.|
About Sigmoid Pharma
Sigmoid Pharma is a specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases. The Company’s Single-Multiple Pill (SmPill®) technology is a versatile delivery system for optimising the formulation of active therapeutic agents and allowing targeted release at the site of disease. Sigmoid’s lead program is CyCol®, a colon-targeted, formulation of cyclosporine that permits local, topical exposure of a powerful immunosuppressant whilst minimizing systemic blood levels, thus offering the potential for an efficacious and safe oral treatment of moderate-severe ulcerative colitis (UC). Another pipeline product is has received US FDA Orphan Designation for Graft-versus-Host Disease. For additional information please visit: http://www.sigmoidpharma.com
Source:Sigmoid Pharma, Ltd